Anju Ghangurde - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Anju Ghangurde's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Anju Ghangurde

Anju Ghangurde

Verified

Executive Editor, Scrip

Mahārāshtra

Final Covers

travel general interest musicHealthcare

Doesn’t Cover

Sex

Journalist Type

-

Seniority Positions

Industries

Medium Formats

-

Content

Total articles 1501

  • Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

    By Lisa Takagi Verified, Joseph Haas Verified, Anju Ghangurde Verified, Vibha Ravi Verified| Scrip Verified Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

    By Lisa Takagi Verified, Joseph Haas Verified, Anju Ghangurde Verified, Vibha Ravi Verified · Scrip

    Apr. 18, 2025

  • India Signals “Systemic Changes” In CGT Regulatory Approach

    By Anju Ghangurde Verified| Citeline Verified India Signals “Systemic Changes” In CGT Regulatory Approach India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of subject expert committees are some of the key changes. Big shifts in India's CGT regulatory approach (Shutterstock)

    By Anju Ghangurde Verified · Citeline

    Apr. 16, 2025

  • Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

    By Lisa Takagi Verified, Joseph Haas Verified, Anju Ghangurde Verified, Vibha Ravi Verified| Scrip Verified Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

    By Lisa Takagi Verified, Joseph Haas Verified, Anju Ghangurde Verified, Vibha Ravi Verified · Scrip

    Apr. 18, 2025

As seen in

Company Info

Scrip

RaiseRight, originally known as ShopWithScrip, was founded in 1994 by two Michigan mothers, Carol Smith and Carol Burgess. The company focuses on innovative fundraising solutions, primarily through gift card fundraising, to support schools, churches, teams, and other organizations across the United States. RaiseRight offers a digital platform that allows organizations to purchase gift cards from major retailers at discounted rates. The difference between the face value and the purchase price is kept by the organization as fundraising revenue. With partnerships with numerous national retailers, RaiseRight provides a wide range of gift cards and has introduced an online shopping feature that enables participants to earn additional funds. The company serves over 50,000 organizations, helping them raise over $900 million since its inception, with nearly $34 million earned in 2024 alone.

Europe, United Kingdom, United Kingdom

+1 800-727-4715

Founded: 1994